CClinicalTrials.gg
CompletedNCT05568316Updated Apr 18, 2023

Impact of Immunonutrition on Nutritional Status in Colorectal Cancer Patients

An interventional study of Preoperative Immunonutrition and Perioperative Immunonutrition in Colorectal Cancer, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2020, registered Aug 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Colorectal cancer is among the top three types of cancer that are most common and causes death worldwide.Nutritional support is widely used in elective colorectal surgery patients, as nutritional status is an important factor affecting clinical outcomes. European Society for Clinical Nutrition and Metabolism (ESPEN, 2016) emphasizes that nutritional supplementation with compounds such as amino acids, arginine, glutamine, and fish oil (omega 3) improves postoperative recovery.

Glutamine; it becomes an essential amino acid under stress. It is an energy substrate for cells such as intestinal mucosal cells and lymphocytes, a material for glutathione synthesis, and a potent antioxidant, which also increases heat shock protein expression. In stressful conditions, arginine is the primary fuel source for T cells and is required for nitric oxide synthesis; therefore, it helps maintain immune function. Omega 3; It plays a role in the treatment of inflammation and improves wound healing. In addition, EPA and DHA increase the immune response by improving lymphocyte function. RNA; They are essential for maturation, proliferation, and function in nearly all biochemical processes, in rapidly proliferating cells such as T cells. studies have shown that immunonutrition (IMN) formulas enriched with biologically active compounds may be more effective in reducing infection complications and shortening postoperative hospital stays.

This study aimed to investigate the additional effects of perioperative compared with preoperative immunonutrition on anthropometric, nutritional, and biochemical parameters, complications, and the length of hospital stay in patients with colorectal cancer.

Read the detailed description

Colorectal cancer is one of the five most common cancer types in men and women worldwide. Cancer malnutrition is seen in patients with colorectal cancer, and this adversely affects the prognosis of the disease. Major operations performed may lead to dysfunction in body homeostasis, impaired defense mechanisms and inflammatory response, increasing the risk of postoperative complications and prolonging hospital stay. Nutritional support products enriched with special compounds such as arginine, glutamine, and omega3 may contribute to the daily energy intake of patients, as well as support the immune system, increase wound healing, and reduce the risk of infection. It is well-documented that preoperative and perioperative compared to no immunonutrition effectively reduce the risk of developing infectious complications and the length of hospital stay. Unless, studies on this subject are very few, especially in our country, Turkey, and their results are contradictory.

The aim of this study is to investigate the additional effects of perioperative compared with preoperative immunonutrition (IMN) on anthropometric, nutritional, biochemical parameters, hospital stay and postoperative complication in patients with colorectal cancer.

The hypotheses of this study are as follows:

H0: There is no difference between the consumption of perioperative compared with preoperative immunonutrition (IMN) on anthropometric, nutritional, biochemical parameters, hospital stay and postoperative complication in patients with colorectal cancer.

H1: Perioperative immunonutrition compare to preoperative has a positive effect in improving the anthropometric measurements, nutritional and biochemical parameters, hospital stay and postoperative complication in patients with colorectal cancer.

Primary purpose: To evaluate the effects of IMN on anthropometric measurements, nutritional and biochemical values of participants in groups.

Secondary purpose: To evaluate the effects of IMN on postoperative complications and length of hospital stay in groups.

The study was conducted as a single-blind prospective randomized controlled clinical trial at a single institution, Haydarpasa Numune Training and Research Hospital General Surgery Clinic, Istanbul, Turkey, between November 2020 and October 2021. The participants included consecutive patients undergoing colorectal cancer surgery.

02

Conditions studied

  • Colorectal Cancer

Keywords

  • colorectal cancer
  • Immunonutrition
  • Nutritional Status
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's enrollment of 50 is below the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Saglik Bilimleri Universitesi is the lead sponsor of 430 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed with colorectal cancer,
  • from 18 years up to 65 years old,
  • To be volunteer,
  • Informed written consent

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18,
  • Above the age of 65
  • To be pregnant,
  • Acute and chronic renal failure, cirrhosis, advanced COPD, mechanical intestinal obstruction, metastasis, presence of sepsis,
  • The ejection fraction is below 35%.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Experimental: Preoperative Immunonutrition (Group 1)

    Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for only 5 days before surgery, in addition to their standard isocaloric diet. Duration: 5 days (preoperative) Dietary therapy: Standard oral nutrition and IMN product for 5 days before operation. The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded.

    Dietary Supplement: Preoperative Immunonutrition

  • Experimental
    Experimental: Perioperative Immunonutrition (Group 2)

    Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet. Duration: 5 days preoperative and 5 days postoperative Dietary therapy: Standard oral nutrition and IMN product for 5 days before and after operation (perioperative). The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded.

    Dietary Supplement: Perioperative Immunonutrition

Interventions

  • Dietary supplementPreoperative Immunonutrition

    Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery. The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.

  • Dietary supplementPerioperative Immunonutrition

    Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet. The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.

06

What researchers measure

Primary outcomes

  1. Nutritional Status

    The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Score \>3: The patient is at risk for nutrition and a nutrition facility is started Score \<3: one should be scanned. If there is a major operation plan, a nutrition plan should also be developed.

    Time frame: At the beginning of the study (7 days before the operation)

  2. Anthropometric Measurements

    Height in meters was measured by researchers at the begining of the study.

    Time frame: At the beginning of the study (7 days before the operation)

  3. Anthropometric Measurements

    Body weight in kilogram was measured by researchers.

    Time frame: At the beginning of the study (7 days before the operation)

  4. Anthropometric Measurements

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: At the beginning of the study (7 days before the operation)

  5. Anthropometric Measurements

    Middle-upper arm circumference (MUAC) in centimeter was measured by using tape measure.

    Time frame: At the beginning of the study (7 days before the operation)

  6. Biochemical Measurements

    Albumin levels in g/dL of participants was recorded from hospital's patients form.

    Time frame: At the beginning of the study (7 days before the operation)

  7. Biochemical Measurements

    Prealbumin levels in mg/dL of participants was recorded from hospital's patients form.

    Time frame: At the beginning of the study (7 days before the operation)

  8. Biochemical Measurements

    Fasting plasma glucose (FPG) mg/dL in of participants was recorded from hospital's patients form.

    Time frame: At the beginning of the study (7 days before the operation)

  9. Biochemical Measurements

    Alanine aminotransferase (ALT) in IU/L of participants was recorded from hospital's patients form.

    Time frame: At the beginning of the study (7 days before the operation)

  10. Biochemical Measurements

    Aspartate aminotransferase (AST) in IU/L of participants was recorded from hospital's patients form.

    Time frame: At the beginning of the study (7 days before the operation)

  11. Biochemical Measurements

    C-reactive protein (CRP) in mg/L of participants was recorded from hospital's patients form.

    Time frame: At the beginning of the study (7 days before the operation)

  12. Anthropometric Measurements

    Body weight in kilogram was measured by researchers.

    Time frame: 7th day after the operation

  13. Anthropometric Measurements

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: 7th day after the operation

  14. Anthropometric Measurements

    Middle-upper arm circumference (MUAC) in centimeter was measured by using tape measure.

    Time frame: 7th day after the operation

  15. Biochemical Measurements

    Albumin levels in g/dL of participants was recorded from hospital's patients form.

    Time frame: On the operation day (Day 0)

  16. Biochemical Measurements

    Prealbumin levels in mg/dL of participants was recorded from hospital's patients form.

    Time frame: On the operation day (Day 0)

  17. Biochemical Measurements

    Fasting plasma glucose (FPG) mg/dL in of participants was recorded from hospital's patients form.

    Time frame: On the operation day (Day 0)

  18. Biochemical Measurements

    Alanine aminotransferase (ALT) in IU/L of participants was recorded from hospital's patients form.

    Time frame: On the operation day (Day 0)

  19. Biochemical Measurements

    Aspartate aminotransferase (AST) in IU/L of participants was recorded from hospital's

    Time frame: On the operation day (Day 0)

  20. Biochemical Measurements

    C-reactive protein (CRP) in mg/L of participants was recorded from hospital's patients form.

    Time frame: On the operation day (Day 0)

  21. Biochemical Measurements

    Albumin levels in g/dL of participants was recorded from hospital's patients form.

    Time frame: 7th day after the operation

  22. Biochemical Measurements

    Prealbumin levels in mg/dL of participants was recorded from hospital's patients form.

    Time frame: 7th day after the operation

  23. Biochemical Measurements

    Fasting Plasma glucose (FPG) mg/dL in of participants was recorded from hospital's patients form.

    Time frame: 7th day after the operation

  24. Biochemical Measurements

    Alanine aminotransferase (ALT) in IU/L of participants was recorded from hospital's patients form.

    Time frame: 7th day after the operation

  25. Biochemical Measurements

    Aspartate aminotransferase (AST) in IU/L of participants was recorded from hospital's patients form.

    Time frame: 7th day after the operation

  26. Biochemical Measurements

    C-reactive protein (CRP) in mg/L of participants was recorded from hospital's patients form.

    Time frame: 7th day after the operation

Secondary outcomes

  1. Postoperative Complications of Participants

    Infections (such as urinary tract, wound infections) and complications were recorded during the postoperative period.

    Time frame: After the operation, up to 30 days.

  2. Lenght of Hospital Stay of Participants

    The length of patients' hospital stay were recorded during the postoperative period.

    Time frame: After the operation, up to 30 days.

07

Study locations

1 site
  • Sağlık Bilimleri University
    Istanbul, Uskudar 34668, Turkey
08

References and documents

Publications

  • Fukatsu K. Role of nutrition in gastroenterological surgery. Ann Gastroenterol Surg. 2019 Feb 25;3(2):160-168. doi: 10.1002/ags3.12237. eCollection 2019 Mar. PubMed 30923785 ↗
  • Karimian J, Hadi A, Salehi-Sahlabadi A, Kafeshani M. The Effect of Arginine Intake on Colorectal Cancer: a Systematic Review of Literatures. Clin Nutr Res. 2019 Jul 25;8(3):209-218. doi: 10.7762/cnr.2019.8.3.209. eCollection 2019 Jul. PubMed 31384599 ↗
  • Bharadwaj S, Trivax B, Tandon P, Alkam B, Hanouneh I, Steiger E. Should perioperative immunonutrition for elective surgery be the current standard of care? Gastroenterol Rep (Oxf). 2016 May;4(2):87-95. doi: 10.1093/gastro/gow008. Epub 2016 Apr 14. PubMed 27081153 ↗
  • Moya P, Soriano-Irigaray L, Ramirez JM, Garcea A, Blasco O, Blanco FJ, Brugiotti C, Miranda E, Arroyo A. Perioperative Standard Oral Nutrition Supplements Versus Immunonutrition in Patients Undergoing Colorectal Resection in an Enhanced Recovery (ERAS) Protocol: A Multicenter Randomized Clinical Trial (SONVI Study). Medicine (Baltimore). 2016 May;95(21):e3704. doi: 10.1097/MD.0000000000003704. PubMed 27227930 ↗
  • Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6. PubMed 27637832 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05568316
Lead sponsor
Saglik Bilimleri Universitesi
Collaborators
Haydarpasa Numune Training and Research Hospital
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Nov 1, 2020
Primary completion
Oct 30, 2021
Completion
Feb 10, 2022
Last update
Apr 18, 2023

Study contacts

BEDRİYE URAL, Dr
principal investigator · Sağlık Bilimleri University
Elvan YILMAZ AKYUZ, Assoc. Prof.
principal investigator · Sağlık Bilimleri University
Cebrail AKYUZ, Assoc. Prof.
principal investigator · Haydarpasa Numune Research and Training Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion